Fobrepodacin (SPR720) is an orally active and potent phosphate prodrug of SPR719 (VXc-486). Fobrepodacin has potent bactericidal activities in vivo.

Fobrepodacin (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1]. Fobrepodacin (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1]. Animal Model: Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)[1]Dosage: 10, 30, 100 mg/kg Administration: Oral gavage; once per day; 5 times per week for 4 weeks Result: Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.